PHARMACY POLICY STATEMENT
North Carolina Marketplace

DRUG NAME	Briumvi (ublituximab-xiiy)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Briumvi, approved by the FDA in 2022, is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Maintenance doses are infused over one hour by the healthcare provider every 24 weeks.

Briumvi (ublituximab-xiiy) will be considered for coverage when the following criteria are met:

Relapsing forms of Multiple Sclerosis (MS)

For **initial** authorization:

1. Member is at least 18 years of age; AND
2. Medication must be prescribed by or in consultation with a neurologist; AND
   Member has a confirmed diagnosis of relapsing multiple sclerosis, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), or active secondary progressive disease (SPMS); AND
   Member has documentation of at least one of the following:
   - Inadequate response to at least one preferred disease-modifying MS drug
   - Highly active disease (aggressive or rapidly evolving) in the expert opinion of the prescriber; AND

   Member has tested negative for active hepatitis B, or a hepatologist has been consulted; AND
   Briumvi will not be used concurrently with another disease-modifying agent for MS.
7. **Dosage allowed/Quantity limit:**